GMED
Globus Medical
Globus Medical historical holders
total: 2
Bares Capital Management Globus Medical transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2025 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q3
Bares Capital Management has been an institutional investor in Globus Medical (GMED) since 2025 Q3. According to 2025 Q3 report, Bares Capital Management holds 521,129 shares with a market value of roughly $29.85M representing 2.75% of their equity portfolio. The fund/company first acquired GMED in 2025 Q3, initially purchasing 521,129 shares.
Does Bares Capital Management still hold GMED?
Yes, Bares Capital Management continues to hold Globus Medical (GMED). According to their 2025 Q3 report, they maintain a position of 521,129 shares valued at approximately $29.85M, representing 2.75% of their equity portfolio.
When did Bares Capital Management first invest in GMED?
Bares Capital Management first invested in Globus Medical (GMED) in 2025 Q3 at the reported quarter-end price of $57.27 per share, acquiring 521,129 shares in their initial purchase.
What is Bares Capital Management's average cost basis for GMED?
Based on historical transaction data, Bares Capital Management's estimated cost basis for Globus Medical (GMED) is approximately $57.27 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $57.27
GMED transactions history by Bares Capital Management
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
2.75%
|
521,129
|
$57.27
|
$29,845,058
|
new
|
+2.75%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.